相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Leah H. Biller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis
Junfeng Huang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Histological growth patterns and molecular analysis of resected colorectal lung metastases
Emanuela Pilozzi et al.
PATHOLOGY RESEARCH AND PRACTICE (2021)
Gene mutation and surgical technique: Suggestion or more?
Yoshikuni Kawaguchi et al.
SURGICAL ONCOLOGY-OXFORD (2020)
Therapeutic targeting of RAS: New hope for drugging the undruggable
Imran Khan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2020)
Colorectal cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers
Alaa Mahmoud et al.
CURRENT PHARMACEUTICAL DESIGN (2020)
Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers
Tyler E. Mattox et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study
Michela Anna Polidoro et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer
To Van Ta et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci et al.
CELLS (2020)
BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
Zi-Nan Li et al.
GASTROENTEROLOGY REPORT (2020)
Highly multiplexed quantifications of 299 somatic mutations in colorectal cancer patients by automated MALDI-TOF mass spectrometry
Chang Xu et al.
BMC MEDICAL GENOMICS (2020)
Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis
Amika Moro et al.
SURGERY (2020)
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Win Topatana et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials
Nagendra S. Yarla et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Development of synthetic lethality in cancer: molecular and cellular classification
Shijie Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
KRasG12C inhibitors in clinical trials: a short historical perspective
Lisa Goebel et al.
RSC MEDICINAL CHEMISTRY (2020)
KRAS Mutation -Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling
Feng Du et al.
THERANOSTICS (2020)
RAC1 as a Therapeutic Target in Malignant Melanoma
Alexa C. Cannon et al.
TRENDS IN CANCER (2020)
Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications
Jun Ye et al.
BIOMEDICAL REPORTS (2020)
A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer
Jing Li et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Quercetin preferentially induces apoptosis in KRAS-mutant colorectal cancer cells via JNK signaling pathways
Yiwen Yang et al.
CELL BIOLOGY INTERNATIONAL (2019)
Next-Generation Sequencing (NGS) Methods Show Superior or Equivalent Performance to Non-NGS Methods on BRAF, EGFR, and KRAS Proficiency Testing Samples
Lea F. Surrey et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
K-RasG12D Has a Potential Allosteric Small Molecule Binding Site
Huizhong Feng et al.
BIOCHEMISTRY (2019)
Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation
Theodosia Charitou et al.
BRITISH JOURNAL OF CANCER (2019)
Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors
Andrea Ponzetta et al.
CELL (2019)
Targeting mTOR for cancer therapy
Hui Hua et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study
Kamila Wojas-Krawczyk et al.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2019)
Drugging an undruggable pocket on KRAS
Dirk Kessler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib
Chi-Shivan Wu et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2019)
A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells
Yuuga Sawata et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2019)
The Crucial Role of CXCL8 and Its Receptors in Colorectal Liver Metastasis
Yaqin Bie et al.
DISEASE MARKERS (2019)
Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
Hui Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation
Bin-bin Jiang et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2019)
Pharmacological targeting of RAS: Recent success with direct inhibitors
John P. O'Bryan
PHARMACOLOGICAL RESEARCH (2019)
The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases
Niccolo Allievi et al.
CHINESE CLINICAL ONCOLOGY (2019)
KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015
Raja Jouini et al.
HELIYON (2019)
Detection of respiratory bacterial pathogens causing atypical pneumonia by multiplex Lightmix® RT-PCR
Karoline Wagne et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2018)
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Manuela Porru et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway
Po-Chen Chu et al.
ONCOGENE (2018)
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence
Diamantis I. Tsilimigras et al.
SURGICAL ONCOLOGY-OXFORD (2018)
Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation
Kathleen A. Boyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition
Lorena Martin-Morales et al.
PLOS ONE (2018)
KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated withReducedImmuneInfiltrationandReactivity in Colorectal Cancer
Neeraj Lal et al.
CLINICAL CANCER RESEARCH (2018)
Colorectal cancer genomics and designing rational trials
Sebastian Mondaca et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Ben Zhao et al.
ONCOTARGET (2017)
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Julien Taieb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Mucosa-associated microbiota signature in colorectal cancer
R. Gao et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
Targeting metabolic reprogramming in KRAS-driven cancers
Kenji Kawada et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS
Emily Chan et al.
INVESTIGATIONAL NEW DRUGS (2017)
Next-generation sequencing: recent applications to the analysis of colorectal cancer
Filippo Del Vecchio et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Current Development Status of MEK Inhibitors
Ying Cheng et al.
MOLECULES (2017)
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience
Jun Gong et al.
ONCOTARGET (2017)
Single-molecule fluorescence imaging of RalGDS on cell surfaces during signal transduction from Ras to Ral
Ryo Yoshizawa et al.
BIOPHYSICS AND PHYSICOBIOLOGY (2017)
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis
Federica Tosi et al.
CLINICAL COLORECTAL CANCER (2017)
MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1
Hongxing Shen et al.
CELL DEATH AND DIFFERENTIATION (2017)
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
Robert P. Jones et al.
BRITISH JOURNAL OF CANCER (2017)
KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay
Sung Hak Lee et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2017)
Multivalent Small-Molecule Pan-RAS Inhibitors
Matthew E. Welsch et al.
CELL (2017)
RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases
Kristoffer Watten Brudvik et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location
Kazunari Sasaki et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis
Hae Su Kim et al.
BMC CANCER (2016)
A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing
Elisabeth Mack et al.
BMC CANCER (2016)
Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases
Georgios A. Margonis et al.
CANCER (2016)
Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down
G. Aaron Hobbs et al.
CANCER CELL (2016)
Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis
Mingyi Zhou et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases
Guillaume Passot et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2016)
Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells
Takashi Shingu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer
Josiah E. Hutton et al.
MOLECULAR & CELLULAR PROTEOMICS (2016)
Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer
Abha Sharma et al.
MOLECULAR DIAGNOSIS & THERAPY (2016)
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Jonathan M. L. Ostrem et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer
Ladan Vakil et al.
TUMOR BIOLOGY (2016)
Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
Wenbin Li et al.
BMC CANCER (2015)
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Beatrix Bencsikova et al.
BMC GASTROENTEROLOGY (2015)
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Sally Temraz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism
Aziz Zaanan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
Yanhong Deng et al.
MOLECULAR ONCOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Jihye Yun et al.
SCIENCE (2015)
KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX
Dae-Won Lee et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Association between KRAS mutation and lung metastasis in advanced colorectal cancer
A. A. L. Pereira et al.
BRITISH JOURNAL OF CANCER (2015)
Structures of Ras superfamily effector complexes: What have we learnt in two decades?
Helen R. Mott et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status
Pilar Garcia-Alfonso et al.
ANGIOGENESIS (2014)
BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
Jing Chen et al.
BMC CANCER (2014)
KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis
Marie Westwood et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Lee S. Schwartzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing
Nishi Kothari et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer
Chun-Chi Lin et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
Yu Imamura et al.
MOLECULAR CANCER (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma
Swati Bisht et al.
MEDICAL ONCOLOGY (2014)
Next Generation Sequencing Improves the Accuracy of KRAS Mutation Analysis in Endoscopic Ultrasound Fine Needle Aspiration Pancreatic Lesions
Dario de Biase et al.
PLOS ONE (2014)
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer
Geraldine Perkins et al.
PHARMACOGENOMICS (2014)
KRAS: feeding pancreatic cancer proliferation
Kirsten L. Bryant et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer
Sandra Van Schaeybroeck et al.
CELL REPORTS (2014)
What is next generation sequencing?
Sam Behjati et al.
ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION (2013)
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
Angell Shieh et al.
BLOOD (2013)
Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
Esther Castellano et al.
CANCER CELL (2013)
A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
Sun Tian et al.
GUT (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Differential Expression of IL-17, 22 and 23 in the Progression of Colorectal Cancer in Patients with K-ras Mutation: Ras Signal Inhibition and Crosstalk with GM-CSF and IFN-γ
Savvas Petanidis et al.
PLOS ONE (2013)
KRAS gene mutation in colorectal cancer
Ivan Roa et al.
REVISTA MEDICA DE CHILE (2013)
The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): A pilot study
Yasser Abd El Kader et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2013)
A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
D. Gonzalez de Castro et al.
BRITISH JOURNAL OF CANCER (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan et al.
CLINICAL CANCER RESEARCH (2012)
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
Thomas H. Cartwright
CLINICAL COLORECTAL CANCER (2012)
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
Tuoping Luo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman et al.
AGING-US (2011)
Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
Francesca Molinari et al.
CLINICAL CANCER RESEARCH (2011)
Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF
Alois H. Lang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras
David Matallanas et al.
MOLECULAR CELL (2011)
The intestinal microbiota and chronic disorders of the gut
Andrew W. DuPont et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice
Magnus Sundstrom et al.
BMC CANCER (2010)
KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
S. Kamel-Reid et al.
Current Oncology (2010)
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Matthias Drosten et al.
EMBO JOURNAL (2010)
Clinical Relevance of KRAS in Human Cancers
Sylwia Jancik et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
Three-dimensionally Specific Inhibition of DNA Repair-Related Genes by Activated KRAS in Colon Crypt Model
Toshiyuki Tsunoda et al.
NEOPLASIA (2010)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells
Cristina P. R. Xavier et al.
CANCER LETTERS (2009)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
Claudia Scholl et al.
CELL (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma
Jehad Abubaker et al.
JOURNAL OF PATHOLOGY (2009)
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Jihye Yun et al.
SCIENCE (2009)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
High-resolution DNA melting analysis for simple and efficient molecular diagnostics
Gudrun H. Reed et al.
PHARMACOGENOMICS (2007)
Development of a novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS)
Keith I. E. McLuckie et al.
NUCLEIC ACIDS RESEARCH (2006)
BRAF mutation and gene methylation frequencies of colorectal tumours with microsatellite instability increase markedly with patient age
B. Iacopetta et al.
GUT (2006)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Liver resection for colorectal metastases - The third hepatectomy
R Adam et al.
ANNALS OF SURGERY (2003)
分享论文
